FDA grants IND clearance for Indapta’s multiple sclerosis treatment trial

Indapta Therapeutics has received clearance from the US Food and Drug Administration (FDA) for its investigational new drug (IND) application, enabling a future Phase I clinical trial of IDP-023 to treat progressive multiple sclerosis (MS).